GM-CSF production in human adenocarcinoma cell lines. 1993

F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
Department of Oncology, Ospedale Infermi, Rimini, Italy.

We describe the production of human granulocyte-macrophage colony-stimulating factor (hGM-CSF), by cell lines established from patients with different stages of breast, lung and colon adenocarcinoma. GM-CSF expression has been identified by immunocytochemistry determination, quantified on conditioned medium with specific ELISA procedure and evaluated by means of proliferation and differentiation of normal human monocytic and granulocytic progenitors. The growth of cell lines after incubation with exogenous GM-CSF and antibody-antiGM-CSF was not modified. To better understand the patho-physiologic role of hGM-CSF in vivo we also estimated its serum levels at diagnosis in 75 patients with breast lung and colon adenocarcinoma and in 69 healthy person. Only two patients showed detectable GM-CSF levels. The lack of growth modulation observed in vitro with exogenous GM-CSF and antibody anti-GM-CSF suggests a non autocrine secretion by adenocarcinoma cells. The serum investigation evidences that the leukocytosis observed in adenocarcinoma patients is unrelated to a GM-CSF constitutive tumor production in vivo.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor

Related Publications

F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
January 1996, Anticancer research,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
July 1998, International journal of cancer,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
June 2007, Neuroscience letters,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
October 1991, Pediatric research,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
June 2011, Veterinary clinical pathology,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
March 2012, Veterinary clinical pathology,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
January 2014, PLoS pathogens,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
February 1990, International journal of cancer,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
August 2016, Thrombosis and haemostasis,
F Monti, and S Szymczuk, and M R Motta, and C Benini, and P P Fattori, and E Pini, and E Pasquini, and W Zoli, and D Amadori, and A Ravaioli
January 1995, Advances in experimental medicine and biology,
Copied contents to your clipboard!